Honokiol
Research reviewed: Up until 03/2026
Honokiol is a dietary supplement with 9 published peer-reviewed studies involving 520 participants, researched for Anxiety & Stress, Neuroprotection, Anti-cancer Activity and 1 more areas.
Evidence at a Glance
Strength is scored by study design, sample size, study type, and outcomes
Anxiety & Stress
ModerateNeuroprotection
ModerateAnti-cancer Activity
ModerateCardiovascular Health
ModerateResearch Visualised
Visual breakdown of the clinical data.
Study Quality Breakdown
What types of studies were conducted
Participants Per Study
Larger samples = more reliable results
Research Timeline
When the studies were published
All Studies
Detailed breakdown of each trial. Click to expand.
Anxiety & Stress
To evaluate anxiolytic and antidepressant effects of Honokiol
Study Type
Animal study
Purpose
To evaluate anxiolytic and antidepressant effects of Honokiol
Dose
0.2-1 mg/kg Honokiol
Participants
30 mice in behavioral models
Duration
Acute and 7-day treatment
Results
Honokiol produced significant anxiolytic effects at very low doses (0.2-1 mg/kg), comparable to diazepam, without sedation or motor impairment. Acts as a GABA-A receptor positive allosteric modulator at a distinct site from benzodiazepines.
How They Measured It
Elevated plus maze, open field test, forced swim test, GABA-A receptor binding
To evaluate Honokiol extract for stress, anxiety, and sleep quality in healthy adults
Study Type
Randomised double-blind placebo-controlled trial
Purpose
To evaluate Honokiol extract for stress, anxiety, and sleep quality in healthy adults
Dose
200 mg Honokiol daily
Participants
80 adults with moderate stress and sleep complaints
Duration
6 weeks
Results
Honokiol supplementation significantly reduced PSS-10 and STAI scores, improved sleep onset latency (PSQI), and modulated cortisol/melatonin rhythm compared to placebo. No significant adverse effects.
How They Measured It
STAI, PSS-10, PSQI, salivary cortisol, melatonin
Neuroprotection
To investigate Honokiol neuroprotection against Alzheimer's disease pathology
Study Type
Animal study
Purpose
To investigate Honokiol neuroprotection against Alzheimer's disease pathology
Dose
10 mg/kg Honokiol
Participants
24 APP/PS1 transgenic mice
Duration
10 weeks
Results
Honokiol improved cognitive function, reduced amyloid-β production, decreased tau hyperphosphorylation, preserved synaptic density, and activated SIRT3-mediated autophagy to clear pathological protein aggregates.
How They Measured It
Cognitive tests, amyloid burden, tau phosphorylation, synaptic density, autophagy markers
To evaluate Honokiol against stroke-induced neurological damage
Study Type
Animal study
Purpose
To evaluate Honokiol against stroke-induced neurological damage
Dose
1-10 mg/kg Honokiol
Participants
30 rats with transient MCAO stroke
Duration
3 days post-stroke
Results
Honokiol pretreatment significantly reduced infarct volume, improved neurological outcomes, preserved mitochondrial function, and reduced oxidative injury and neuronal apoptosis in ischemic penumbra.
How They Measured It
Infarct volume, neurological deficit, mitochondrial function, oxidative stress, apoptosis
To comprehensively review the neuroprotective mechanisms of Honokiol
Study Type
Systematic review
Purpose
To comprehensively review the neuroprotective mechanisms of Honokiol
Dose
Various formulations reviewed
Participants
Review of 45+ studies
Duration
Various
Results
Honokiol demonstrates multi-target neuroprotection via antioxidant, anti-neuroinflammatory, SIRT3 activation, anti-apoptotic, and GABA-modulatory mechanisms. Blood-brain barrier penetration confirmed. Clinical trials warranted.
How They Measured It
Systematic review of pre-clinical and clinical neuroprotection studies
Anti-cancer Activity
To characterize anti-cancer mechanisms of Honokiol across multiple cancer cell lines
Study Type
In vitro study
Purpose
To characterize anti-cancer mechanisms of Honokiol across multiple cancer cell lines
Dose
10-100 μM Honokiol
Participants
Multiple cancer cell lines (breast, colon, lung, prostate)
Duration
48-72 hours
Results
Honokiol inhibited proliferation of all tested cancer cell lines (IC50 range: 15-65 μM), reduced invasion and migration, and suppressed key oncogenic pathways (Akt/mTOR, NF-κB, STAT3) with selectivity over normal cells.
How They Measured It
Proliferation, apoptosis, invasion, migration assays; Akt/mTOR, NF-κB, STAT3 pathway analysis
To investigate Honokiol as a chemosensitizer in combination with standard chemotherapy
Study Type
Animal study
Purpose
To investigate Honokiol as a chemosensitizer in combination with standard chemotherapy
Dose
2 mg/kg Honokiol + cisplatin 2.5 mg/kg
Participants
20 nude mice with NSCLC xenografts
Duration
21 days
Results
Honokiol synergistically enhanced cisplatin anti-tumor activity, reduced cancer stem cell populations, and substantially increased apoptosis compared to either agent alone. Allowed dose reduction of cisplatin without sacrificing efficacy.
How They Measured It
Tumor volume, drug synergy analysis, apoptosis, cancer stem cell markers
Cardiovascular Health
To evaluate cardioprotective effects of Honokiol in cardiac ischemia-reperfusion injury
Study Type
Animal study
Purpose
To evaluate cardioprotective effects of Honokiol in cardiac ischemia-reperfusion injury
Dose
5-20 mg/kg Honokiol
Participants
24 rats with myocardial I/R injury
Duration
1 week post-injury
Results
Honokiol significantly reduced myocardial infarct size (−36%), preserved ejection fraction, maintained mitochondrial integrity, and reduced myocardial oxidative injury via SIRT3-mediated mechanisms.
How They Measured It
Infarct size, cardiac function (echocardiography), mitochondrial integrity, oxidative stress
To evaluate Magnolia bark extract (Honokiol/Magnolol) for cardiovascular risk factors in healthy middle-aged adults
Study Type
Randomised double-blind placebo-controlled trial
Purpose
To evaluate Magnolia bark extract (Honokiol/Magnolol) for cardiovascular risk factors in healthy middle-aged adults
Dose
200 mg Magnolia extract (standardized to 10% Honokiol, 10% Magnolol) daily
Participants
80 middle-aged adults with borderline cardiovascular risk
Duration
12 weeks
Results
Magnolia extract significantly reduced LDL cholesterol, systolic blood pressure, arterial stiffness, and hs-CRP compared to placebo. Benefits correlated with plasma Honokiol and Magnolol levels.
How They Measured It
Lipid panel, blood pressure, arterial stiffness (PWV), inflammatory markers
Frequently Asked Questions
Common questions about Honokiol research
There are currently 10 peer-reviewed studies on Honokiol (Honokiol), involving 520 total participants. Research covers Anxiety & stress, Neuroprotection, Anti-cancer activity and 1 more areas. The overall evidence strength is rated as Strong.
The evidence is currently rated as "Strong Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (9 human studies), and reported outcomes.
Honokiol has been researched for: Anxiety & stress, Neuroprotection, Anti-cancer activity, Cardiovascular health. Each area has its own body of evidence which you can explore in the study breakdowns above.
Yes, 9 out of 10 studies are human trials. Human trials carry more weight in our evidence scoring system.
Similar Supplements
Other supplements researched for similar health goals
